rs2736871

This is a intron variant variant in the ST3GAL1 gene.

Research that mentions this SNP (1)

Genetic predictors of risk and resilience in psychiatric disorders: A cross‐disorder genome‐wide association study of functional impairment in major depressive disorder, bipolar disorder, and schizophrenia
AssociationN=2,246Lauren M. McGrath et al.(2013)· American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

A genome-wide association study of 2,246 psychiatric patients across three disorders (MDD, bipolar disorder, schizophrenia) identified variants in ADAMTS16 showing the strongest association with physical health-related quality of life (rs16875288, p = 5.87 × 10⁻⁸, approaching but not exceeding genome-wide significance). The findings demonstrate that genetic variation in functional impairment operates as a distinct axis independent from symptom severity, with psychiatric symptoms accounting for less than one-third of the variance in functional outcomes.

Traits studied:Bipolar DisorderEmployment statusFunctional impairmentHealth-related quality of lifeMajor Depressive DisorderMental health componentPhysical health componentSchizophrenia

About ST3GAL1

The protein encoded by this gene is a type II membrane protein that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose-containing substrates. The encoded protein is normally found in the Golgi but can be proteolytically processed to a soluble form. Correct glycosylation of the encoded protein may be critical to its sialyltransferase activity. This protein, which is a member of glycosyltransferase family 29, can use the same acceptor substrates as does sialyltransferase 4B. Two transcript variants encoding the same protein have been found for this gene. Other transcript variants may exist, but have not been fully characterized yet. [provided by RefSeq, Jul 2008]

View all ST3GAL1 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…